(S (NP-SBJ Alpha-lipoic/JJ acid/NN) (VP is/VBZ (NP-PRD (NP a/DT potent/JJ inhibitor/NN) (PP of/IN (NP (NP NF-kappa/NN B/NN activation/NN) (PP in/IN (NP human/JJ T/NN cells/NNS)))))) ./.)
(S (NP-SBJ (NP Acquired/VBN immunodeficiency/NN syndrome/NN) (PRN -LRB-/-LRB- (NP AIDS/NN) -RRB-/-RRB-)) (VP results/VBZ (PP from/IN (NP (NP infection/NN) (PP with/IN (NP (NP a/DT human/JJ immunodeficiency/NN virus/NN) (PRN -LRB-/-LRB- (NP HIV/NN) -RRB-/-RRB-)))))) ./.)
(S-COOD (S (NP-SBJ (NP The/DT (NP (NP long/JJ terminal/JJ repeat/NN) (PRN -LRB-/-LRB- (NP LTR/NN) -RRB-/-RRB-)) region/NN) (PP of/IN (NP HIV/NN proviral/JJ DNA/NN))) (VP contains/VBZ (NP (NP binding/VBG sites/NNS) (PP for/IN (NP (NP nuclear/JJ factor/NN kappa/NN B/NN) (PRN -LRB-/-LRB- (NP NF-kappa/NN B/NN) -RRB-/-RRB-)))))) ,/, and/CC (S (NP-SBJ-1 this/DT transcriptional/JJ activator/NN) (VP appears/VBZ (S (NP-SBJ *-1/-NONE-) (VP to/TO (VP regulate/VB (NP HIV/NN activation/NN)))))) ./.)
(S (NP-SBJ Recent/JJ findings/NNS) (VP suggest/VBP (NP (NP an/DT involvement/NN) (PP of/IN (NP (NP reactive/JJ oxygen/NN species/NNS) (PRN -LRB-/-LRB- (NP ROS/NN) -RRB-/-RRB-))) (PP in/IN (NP (NP signal/NN transduction/NN pathways/NNS) (VP leading/VBG (PP to/TO (NP NF-kappa/NN B/NN activation/NN))))))) ./.)
(S (NP-200 The/DT present/JJ study/NN) (VP was/VBD (VP based/VBN (NP *-200/-NONE-) (PP on/IN (NP reports/NNS (SBAR that/IN (S-COOD (S (NP-SBJ (NP antioxidants/NNS) (SBAR (WHNP-2 which/WDT) (S (NP-SBJ *T*-2/-NONE-) (VP eliminate/VBP (NP ROS/NN))))) (VP should/MD (VP-COOD (VP block/VB (NP-3 (NP the/DT activation/NN) (PP of/IN (NP NF-kappa/NN B/NN)))) and/CC (VP (ADVP subsequently/RB) (NP=3 HIV/NN transcription/NN))))) ,/, and/CC thus/RB (S (NP-SBJ-4 antioxidants/NNS) (VP can/MD (VP be/VB (VP used/VBN (NP *-4/-NONE-) (PP as/IN (NP (NP therapeutic/JJ agents/NNS) (PP for/IN (NP AIDS/NN)))))))))))))) ./.)
(S (NP-SBJ-5 (NP Incubation/NN) (PP of/IN (NP (NP Jurkat/NN T/NN cells/NNS) (PRN -LRB-/-LRB- (NP (QP 1/CD x/CC 10-LRB-6-RRB-/CD) cells\/ml/NNS) -RRB-/-RRB-))) (PP with/IN (NP a/DT natural/JJ thiol/NN (ADJP-COOD (ADJP antioxidant/NN) ,/, (ADJP alpha-lipoic/JJ)) acid/NN)) ,/, (PP prior/JJ to/TO (NP (NP the/DT stimulation/NN) (PP of/IN (NP cells/NNS))))) (VP was/VBD (VP found/VBN (S (NP-SBJ *-5/-NONE-) (VP to/TO (VP inhibit/VB (NP (NP NF-kappa/NN B/NN activation/NN) (VP induced/VBN (NP */-NONE-) (PP-COOD (PP by/IN (NP (NP tumor/NN necrosis/NN factor-alpha/NN) (PRN -LRB-/-LRB- (NP 25/CD ng\/ml/NN) -RRB-/-RRB-))) or/CC (PP by/IN (NP (NP phorbol/NN 12-myristate/NN 13-acetate/NN) (PRN -LRB-/-LRB- (NP 50/CD ng\/ml/NN) -RRB-/-RRB-))))))))))) ./.)
(S-COOD (S (NP-SBJ-6 (NP The/DT inhibitory/JJ action/NN) (PP of/IN (NP alpha-lipoic/JJ acid/NN))) (VP was/VBD (VP found/VBN (S (NP-SBJ *-6/-NONE-) (VP to/TO (VP be/VB (ADJP-PRD very/RB potent/JJ) (SBAR as/IN (S (NP-SBJ-7 (QP only/RB 4/CD) mM/NN) (VP was/VBD (VP needed/VBN (NP *-7/-NONE-) (PP for/IN (NP a/DT complete/JJ inhibition/NN)))))))))))) ,/, whereas/IN (S (NP-SBJ-8 20/CD mM/NN) (VP was/VBD (VP required/VBN (NP *-8/-NONE-) (PP for/IN (NP N-acetylcysteine/NN))))) ./.)
(S (NP-SBJ These/DT results/NNS) (VP indicate/VBP (SBAR that/IN (S (NP-SBJ alpha-lipoic/JJ acid/NN) (VP may/MD (VP be/VB (ADJP-PRD effective/JJ) (PP in/IN (NP AIDS/NN therapeutics/NNS))))))) ./.)
